{"id":32861,"date":"2025-05-06T15:10:47","date_gmt":"2025-05-06T07:10:47","guid":{"rendered":"https:\/\/flcube.com\/?p=32861"},"modified":"2025-05-06T15:10:48","modified_gmt":"2025-05-06T07:10:48","slug":"chengdu-origen-announces-first-patient-dosing-of-kh658-in-wet-amd-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32861","title":{"rendered":"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial"},"content":{"rendered":"\n

China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene therapy co-developed by compatriot firm Chengdu Kanghong Pharmaceutical Group Co., Ltd.’s (SHE: 002773<\/a>) US unit Vanotech Inc., in the dosage escalation Phase I VAN-2401 study for wet Age-related Macular Degeneration (wet AMD).<\/p>\n\n\n\n

KH658 Mechanism and Preclinical Results<\/strong>
KH658 is a recombinant adeno-associated virus vector that encodes a human VEGF receptor fusion protein. In preclinical studies of wet AMD disease models, suprachoroidal space administration of KH658 resulted in the retention of the transgene product in the retina for prolonged periods and prevented disease progression. This innovative approach holds promise for addressing unmet medical needs in wet AMD treatment.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene…<\/p>\n","protected":false},"author":1,"featured_media":32865,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,66,653,44,4045,1335,4046],"class_list":["post-32861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-gene-therapy","tag-kanghong-pharmaceutical","tag-ophthalmology","tag-origen-biotechnology","tag-she-002773","tag-vanotech"],"yoast_head":"\nChengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene therapy co-developed by compatriot firm Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s (SHE: 002773) US unit Vanotech Inc., in the dosage escalation Phase I VAN-2401 study for wet Age-related Macular Degeneration (wet AMD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32861\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial\" \/>\n<meta property=\"og:description\" content=\"China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene therapy co-developed by compatriot firm Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s (SHE: 002773) US unit Vanotech Inc., in the dosage escalation Phase I VAN-2401 study for wet Age-related Macular Degeneration (wet AMD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32861\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-06T07:10:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T07:10:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0506.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial\",\"datePublished\":\"2025-05-06T07:10:47+00:00\",\"dateModified\":\"2025-05-06T07:10:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861\"},\"wordCount\":128,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0506.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Gene therapy\",\"Kanghong Pharmaceutical\",\"Ophthalmology\",\"Origen Biotechnology\",\"SHE: 002773\",\"Vanotech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32861#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32861\",\"name\":\"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0506.webp\",\"datePublished\":\"2025-05-06T07:10:47+00:00\",\"dateModified\":\"2025-05-06T07:10:48+00:00\",\"description\":\"China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene therapy co-developed by compatriot firm Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s (SHE: 002773) US unit Vanotech Inc., in the dosage escalation Phase I VAN-2401 study for wet Age-related Macular Degeneration (wet AMD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32861\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0506.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0506.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32861#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial - Insight, China's Pharmaceutical Industry","description":"China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene therapy co-developed by compatriot firm Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s (SHE: 002773) US unit Vanotech Inc., in the dosage escalation Phase I VAN-2401 study for wet Age-related Macular Degeneration (wet AMD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32861","og_locale":"en_US","og_type":"article","og_title":"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial","og_description":"China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene therapy co-developed by compatriot firm Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s (SHE: 002773) US unit Vanotech Inc., in the dosage escalation Phase I VAN-2401 study for wet Age-related Macular Degeneration (wet AMD).","og_url":"https:\/\/flcube.com\/?p=32861","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-06T07:10:47+00:00","article_modified_time":"2025-05-06T07:10:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0506.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32861#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32861"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial","datePublished":"2025-05-06T07:10:47+00:00","dateModified":"2025-05-06T07:10:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32861"},"wordCount":128,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32861#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0506.webp","keywords":["Clinical trial approval \/ initiation","Gene therapy","Kanghong Pharmaceutical","Ophthalmology","Origen Biotechnology","SHE: 002773","Vanotech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32861#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32861","url":"https:\/\/flcube.com\/?p=32861","name":"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32861#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32861#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0506.webp","datePublished":"2025-05-06T07:10:47+00:00","dateModified":"2025-05-06T07:10:48+00:00","description":"China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene therapy co-developed by compatriot firm Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s (SHE: 002773) US unit Vanotech Inc., in the dosage escalation Phase I VAN-2401 study for wet Age-related Macular Degeneration (wet AMD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32861#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32861"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32861#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0506.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0506.webp","width":1080,"height":608,"caption":"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32861#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0506.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32861"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32861\/revisions"}],"predecessor-version":[{"id":32866,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32861\/revisions\/32866"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32865"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}